NCT07418138Completed
Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation
Efficacy and Safety of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
Based on the follow-up data of hepatocellular carcinoma (HCC) patients undergoing liver transplantation from the China Liver Transplant Registry (CLTR) and the First Affiliated Hospital of Xi'an Jiaotong University, patients who met the inclusion criteria were assessed for tumor response, post-transplant tumor recurrence, and survival rates. Statistical analysis was performed to evaluate patient prognosis and to identify risk factors affecting outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 484 (actual)
- First submitted
- 4 Feb 2026
- Start date
- 1 Jan 2015
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Hu Liangshuo
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07418138
What you commit to
- Study type: Observational
- Participants enrolled: 484
- From 1 Jan 2015 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- living-donor liver transplantation or re-transplantation;
- concurrent active malignancy other than HCC;
Age
- age \<18 years or \>75 years;
Other
- incomplete key baseline data or follow-up information.
Who the study is looking for
- Age ≥ 18 years and ≤ 75 years;
- HCC diagnosis confirmed through imaging and elevated serum alpha-fetoprotein (AFP);
- Underwent liver transplantation for hepatocellular carcinoma.
- Underwent primary (first-time) liver transplantation.
- Availability of complete clinical and follow-up data for analysis.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Affiliated Hospital Xian Jiaotong University Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.